Neebcure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
- Revenue Growth -36.16%
- Profit Growth 22.50%
- Ebitda 33.74%
- Net Worth -85.15%
- Total Assets -52.72%
About Neebcure Pharmaceuticals
Neebcure Pharmaceuticals Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 April 2017 (Seven years and nine months 7 days old ). Its registered office is in Etah, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 M.
Meenu Maheshwari and Adarsh Maheshwari serve as directors at the Company.
Company Details
- Location
Etah, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U51909UP2017PTC092478
- Company No.
092478
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Neebcure Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Adarsh Maheshwari  | Managing Director | 24-Apr-2017 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Meenu Maheshwari | Director | 24-Apr-2017 | Current |
Financial Performance of Neebcure Pharmaceuticals.
Neebcure Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 36.16% decrease. The company also saw a substantial improvement in profitability, with a 22.5% increase in profit. The company's net worth observed a substantial decline by a decrease of 85.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neebcure Pharmaceuticals?
In 2019, Neebcure Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Aug 2017 | Others | ₹1.50 M | Open |
How Many Employees Work at Neebcure Pharmaceuticals?
Unlock and access historical data on people associated with Neebcure Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neebcure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neebcure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.